Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Investor Resources

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

H.C. Wainwright & Co.
Swayampakula Ramakanth, Ph.D.

Investor News Alerts

Use the button below to email us and receive the latest investor focused news from Isoray.

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Dr. Peter Orio Showcases the Elegance and Simplicity of Brachytherapy for Prostate Cancer

Boston Herald Reporter Alexi Cohan recently joined Dr. Peter Orio on the “front lines” in order to learn more about brachytherapy for prostate...

Isoray Collaborates With Texas Oncology to Fill Void in Training Programs For Next Generation of Brachytherapists

RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering...

Webinar: Transitioning Isotopes for Prostate Brachytherapy – April 17th, 2019

After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and...

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year   RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN:...

Blu Build Featured on WCIV-TV in Charleston, SC

https://write2market.wistia.com/medias/jt4rxq27n7 WCIV-TV reports on the world’s first use of the Blu Build Cesium-131 brachytherapy delivery...